Quantitative LC-MS Profiling of PRMT5 and Methionine Cycle Metabolites
PRMT5 is a high-value therapeutic target across many cancers, especially in tumors with altered methionine cycle metabolism. Accurate measurement of PRMT5 activity requires precise quantification of the metabolites directly involved in its biochemical pathway.
Panome Bio’s PRMT5 Targeted Metabolomics Panel provides sensitive, reproducible LC-MS measurement of the core metabolites that define PRMT5 activity, enabling deeper insights for oncology research, mechanism-of-action studies, and response evaluation.
What This Panel Measures
Core PRMT5 and methionine cycle metabolites including:
- SDMA (Symmetric Dimethylarginine)
- ADMA (Asymmetric Dimethylarginine)
- SAM (S-adenosylmethionine)
- MTA (Methylthioadenosine)
These metabolites provide the most direct readout of PRMT5 pathway activity and downstream biological consequences.
Key Advantages:
- Highly reproducible relative quantification of SDMA, ADMA, SAM, MTA, and related compounds, ideal for comparing treated vs. untreated, or pre- vs. post-treatment samples.
- Specialized MS2-based LC/MS method allows us to reliably distinguish and quantify the isomeric pair of SDMA and ADMA.
- Robust measurement across a wide dynamic range for highly reactive metabolites like SAM and MTA by utilizing internal controls.
- Validated method supports a wide range of biological samples, supporting both clinical and preclinical studies.
Get High-Resolution Insights Into PRMT5 Biology
Our targeted metabolomics workflow provides a powerful, quantitative approach for characterizing PRMT5 pathway activity with clarity and confidence.
Frequently Asked Questions
What is the PRMT5 Targeted Metabolomics Panel?
It is a quantitative LC-MS panel that measures core PRMT5 and methionine cycle metabolites — SDMA, ADMA, SAM, and MTA — to provide a direct readout of PRMT5 pathway activity.
Which metabolites does the PRMT5 panel measure?
The panel measures SDMA (symmetric dimethylarginine), ADMA (asymmetric dimethylarginine), SAM (S-adenosylmethionine), and MTA (methylthioadenosine), along with related methionine cycle compounds.
Why is PRMT5 an important target in cancer research?
PRMT5 is a high-value therapeutic target across many cancers, particularly tumors with altered methionine cycle metabolism, making precise measurement of its pathway activity valuable for oncology and mechanism-of-action studies.
Can this panel distinguish between the isomeric compounds SDMA and ADMA?
Yes. Panome Bio uses a specialized MS2-based LC/MS method that reliably distinguishes and quantifies the isomeric pair of SDMA and ADMA.